History of immunology and tumor immunity1893
Use of live bacteria and bacterial lysates to treat tumors-"Coley's Toxins" (William B. Coley).
History of immunology and tumor immunity1957
Thomas and Burnet first proposed the theory of cancer immunosurveillance.
History of immunology and tumor immunity1958
Discovery of human leukocyte antigens (Jean Dausset and others).
History of immunology and tumor immunity1959
Discovery of antibody structure (independently elucidated by Gerald Edelman and Rodney Porter).
History of immunology and tumor immunity1973
Dendritic Cells first described by Ralph M. Steinman.
History of immunology and tumor immunity1974
T-cell restriction to MHC (Rolf Zinkernagel and (Peter C. Doherty)
History of immunology and tumor immunity1975
Generation of monoclonal antibodies (Georges Köhler) and (César Milstein).
History of immunology and tumor immunity1976
Identification of somatic recombination of immunoglobulin genes (Susumu Tonegawa)
History of immunology and tumor immunity1983
Discovery of the T cell antigen receptor TCR (Ellis Reinherz) (Philippa Marrack) and (John Kappler) (James Allison)
History of immunology and tumor immunity1985
Large doses of IL-2 were shown to be effective when administered to patients with established, metastatic cancers by enhancing T-cell production.
History of immunology and tumor immunity1988
Autologous TIL used to treat melanoma patients.
History of immunology and tumor immunity1992
Honjo first identified PD-1 as an inducible gene on activated T-lymphocytes, and this discovery significantly contributed to the establishment of cancer immunotherapy principle by PD-1 blockade.
History of immunology and tumor immunity1995
First Dendritic cell vaccine trial reported by Mukherji et al.
History of immunology and tumor immunity1996
James Allison was the first to show that antibody blockade of CTLA-4 could lead to enhanced anti-tumor immune responses and tumor rejection.
History of immunology and tumor immunity1997
First antibody treatment approved for use by the FDA(rituximab).
History of immunology and tumor immunity2010
The first autologous cell-based cancer vaccine, PROVENGE, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer.
History of immunology and tumor immunity2011
First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA.
History of immunology and tumor immunity2014
A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma.
History of immunology and tumor immunity2017
The first autologous CAR T-cell therapy Kymriah is approved for the treatment of pediatric B-ALL.
Two independent clinical studies provided solid evidence that neoantigen-based cancer vaccines could be developed to elicit potent neoantigen-specific T ce
In personalized tumor immunotherapy, appropriate drug forms are selected for clinical treatment according to different indications based on the identification and screening of tumor-specific neoantigens. We developed Likang Neoantigen Epitope Analysis (LNEA) platform and dendritic cell (DC) loaded with tumor-specific neoantigens, neoantigen specific T cell (Neo-T), transgenic T cell (TCR-T), and etc. which may enable us to predict the presence of unique neoantigens in tumor cells of patients, and based on multiple product lines, gradually promote individualized tumor immunotherapy to clinical application.